Cargando…
The Noradrenaline Metabolite MHPG Is a Candidate Biomarker from the Manic to the Remission State in Bipolar Disorder I: A Clinical Naturalistic Study
Remission is the primary goal of treatment for bipolar disorder I (BDI). Metabolites of noradrenaline and dopamine, 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA), respectively, are reduced by treatment with antipsychotics, but whether these phenomena are caused by antipsychotics...
Autores principales: | Kurita, Masatake, Nishino, Satoshi, Numata, Yukio, Okubo, Yoshiro, Sato, Tadahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074114/ https://www.ncbi.nlm.nih.gov/pubmed/24971450 http://dx.doi.org/10.1371/journal.pone.0100634 |
Ejemplares similares
-
The noradrenaline metabolite MHPG is a candidate biomarker between the depressive, remission, and manic states in bipolar disorder I: two long-term naturalistic case reports
por: Kurita, Masatake, et al.
Publicado: (2015) -
Plasma Brain-Derived Neurotrophic Factor Levels Predict the Clinical Outcome of Depression Treatment in a Naturalistic Study
por: Kurita, Masatake, et al.
Publicado: (2012) -
Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode
por: Kurita, Masatake
Publicado: (2016) -
Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
por: Takeyoshi, Kenji, et al.
Publicado: (2016) -
Need for medication to complement catecholamines in smoking cessation of hardcore smokers
por: Kawai, Atsuko, et al.
Publicado: (2017)